Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $58
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $53 to $58.
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $53 to $58.